LAWRENCE, Mass., March 13, 2018 /PRNewswire/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company focused on advancing renal care, announced new findings further demonstrating the benefits of home hemodialysis with the NxStage® System One™, including on-site hemodialysis at skilled nursing facilities, solo home hemodialysis, and more frequent home hemodialysis. The collection of data was presented at the recent Annual Dialysis Conference (ADC) in Orlando, Florida.
"Our continuing research shows that more frequent home hemodialysis is a clinically differentiated therapy," said Joe Turk, President, NxStage Medical, Inc. "Expansion of home hemodialysis in patient populations that have lacked access holds great potential to improve population outcomes."
On-Site Hemodialysis in Skilled Nursing Facilities:
Eric Weinhandl, PhD, MS, NxStage Clinical Epidemiologist and Adjunct Assistant Professor at the University of Minnesota, presented a study of hospitalization and related Medicare expenditures in the roughly 8,000 nursing home residents per year who initiated dialysis. The study found that these patients were predominantly elderly, spent 44 days per year in the hospital, and accumulated over $38,000 in Medicare payments per year for inpatient care.
"With an aging population, the number of nursing home residents needing dialysis is expected to grow," said Dr. Weinhandl. "Using the NxStage System One to provide more frequent and
Solo Home Hemodialysis:
Another abstract illustrated findings from the NxStage patient preference survey that supported FDA clearance of the NxStage System One for solo home hemodialysis. The findings showed that within 32 subgroups, current home hemodialysis patients would prefer solo home hemodialysis over in-center hemodialysis, even if risk of death were significantly elevated on solo home hemodialysis.
More Frequent Home Hemodialysis:
NxStage researchers also presented new data that were collected with its remote patient management system, Nx2me Connected Health®, and showed that patients on more frequent home hemodialysis had lower risk of intradialytic hypotension than patients on conventional in-center hemodialysis.
"Data consistently show that more frequent home hemodialysis has cardiovascular benefits," said Dr. Weinhandl. "The therapy may be especially useful in settings with historically poor clinical and economic outcomes, such as nursing homes."
Full abstracts can be read online at http://annualdialysisconference.org/abstracts/.
Visit www.NxStage.com for more information about therapy options with the NxStage System One.
The NxStage System One is a prescription device and, like all medical devices, involves some risks. The risks associated with hemodialysis treatments in any environment include, but are not limited to, high blood pressure, fluid overload, low blood pressure, heart-related issues, and vascular access complications. The medical devices used in hemodialysis therapies may add additional risks including air entering the bloodstream, and blood loss due to clotting or accidental disconnection of the blood tubing set.
A trained and qualified patient may dialyze alone, without a care partner present (solo home hemodialysis), provided the patient and physician agree that solo home hemodialysis is appropriate. Certain risks associated with hemodialysis treatment are increased when performing solo home hemodialysis because no one is present to help the patient respond to health emergencies. If patients experience needles coming out, blood loss, or very low blood pressure during solo home hemodialysis, they may lose consciousness or become physically unable to correct the health emergency. Losing consciousness or otherwise becoming impaired during any health emergency while alone could result in significant injury or death. Additional ancillary devices and training are required when performing solo home hemodialysis. Patients should consult with their physician to understand the risks and responsibilities associated with home and/or more frequent hemodialysis, and solo home hemodialysis using the NxStage System One. Additionally, the reported benefits of home and/or more frequent hemodialysis may not be experienced by all patients. Patients and providers are encouraged to contact their state regulators to discuss state-specific regulations that may impact dialysis in the skilled nursing facility setting.
About the NxStage System One
The NxStage System One is the first and only truly portable hemodialysis system cleared specifically by the FDA for home hemodialysis, home nocturnal hemodialysis and solo home hemodialysis. Its simplicity and revolutionary size (just over a foot tall) are intended to allow convenient use in patients' homes and give patients the freedom to travel with their therapy. When combined with the NxStage PureFlow SL Dialysis Preparation System, patients are able to further simplify, using ordinary tap water to create dialysis fluid on demand. Unlike conventional hemodialysis systems, the System One requires no special infrastructure to operate. Under the guidance of their physician, patients can use the NxStage System One, with their trained partners (or for patients prescribed to receive solo dialysis, alone), where, how and when it best meets their needs, including while they are sleeping - at home or on vacation and at a medically appropriate treatment frequency. In addition, NxStage's Nx2me Connected Health platform collects important NxStage System One and patient information for flexible viewing, monitoring and reporting that may improve patient management and patient retention, as well as simplify alternative site care. www.nxstage.com.
About NxStage Medical
NxStage Medical, Inc. (Nasdaq: NXTM) is a leading medical technology company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of ESRD and acute kidney failure. NxStage also has established a small number of dialysis clinics. For more information on NxStage and its products and services, please visit the Company's websites at www.nxstage.com and www.nxstagekidneycare.com.
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2017. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Kristen K. Sheppard, Esq.
1Cornelis T, Kotanko P, Goffin E, van der Sande FM, Kooman JP, Chan CT.
Intensive hemodialysis in the (nursing) home: the bright side of geriatric ESRD
care? Semin Dial. 2012 Nov-Dec;25(6):605-10. doi: 10.1111/sdi.12011.
2Yang A, Lee WY, Hocking K. Survival comparison of daily home hemodialysis vs.
conventional in the nursing home setting. Nephrol News Issues. 2015
SOURCE NxStage Medical, Inc.